Literature DB >> 17455036

Test of Memory Malingering (TOMM) scores are not affected by chronic pain or depression in patients with fibromyalgia.

Grant L Iverson1, Judy Le Page, Barry E Koehler, Kamran Shojania, Maziar Badii.   

Abstract

Neuropsychologists routinely give effort tests, such as the Test of Memory Malingering (TOMM). When a person fails one of these tests, the clinician must try to determine whether the poor performance was due to suboptimal effort or to chronic pain, depression, or other problems. Participants were 54 community-dwelling patients who met American College of Rheumatology criteria for fibromyalgia (FM). In addition to the TOMM, they completed the Beck Depression Inventory-Second Edition, Multidimensional Pain Inventory-Version 1, Oswestry Disability Index-2.0, British Columbia Cognitive Complaints Inventory, and the Fibromyalgia Impact Questionnaire. The majority endorsed at least mild levels of depressive symptoms (72%), and 22% endorsed "severe" levels of depression. The average scores on the TOMM were 48.8 (SD = 1.9, range = 40-50) for Trial 1, 49.8 (SD = 0.5, range = 48-50) for Trial 2, and 49.6 (SD = 0.9, range = 45-50) for Retention. Despite relatively high levels of self-reported depression, chronic pain, and disability, not a single patient failed the TOMM. In this study, the TOMM was not affected by chronic pain, depression, or both.

Entities:  

Mesh:

Year:  2007        PMID: 17455036     DOI: 10.1080/13854040600611392

Source DB:  PubMed          Journal:  Clin Neuropsychol        ISSN: 1385-4046            Impact factor:   3.535


  9 in total

Review 1.  [Symptom and complaint validation of chronic pain in social medical evaluation. Part II: Analysis levels and assessment recommendations].

Authors:  R Dohrenbusch
Journal:  Schmerz       Date:  2009-06       Impact factor: 1.107

Review 2.  [Cognitive impairment in patients suffering from fibromyalgia. An underestimated problem].

Authors:  T Schmidt-Wilcke; P Wood; R Lürding
Journal:  Schmerz       Date:  2010-02       Impact factor: 1.107

3.  Fibrofog in Daily Life: An Examination of Ambulatory Subjective and Objective Cognitive Function in Fibromyalgia.

Authors:  Anna L Kratz; Daniel Whibley; Samsuk Kim; Martin Sliwinski; Daniel Clauw; David A Williams
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-11-09       Impact factor: 4.794

4.  Utility of the test of memory malingering (TOMM) in children ages 4-7 years with and without ADHD.

Authors:  Heather E Schneider; John W Kirk; E Mark Mahone
Journal:  Clin Neuropsychol       Date:  2014-09-23       Impact factor: 3.535

5.  Adjudication of fibromyalgia syndrome: challenges in the medicolegal arena.

Authors:  Mary-Ann Fitzcharles; Peter A Ste-Marie; Angela Mailis; Yoram Shir
Journal:  Pain Res Manag       Date:  2014 Nov-Dec       Impact factor: 3.037

Review 6.  Fibromyalgia and disability adjudication: no simple solutions to a complex problem.

Authors:  Manfred Harth; Warren R Nielson
Journal:  Pain Res Manag       Date:  2014 Nov-Dec       Impact factor: 3.037

7.  Assessment of feigned cognitive impairment in severe traumatic brain injury patients with the Forced-choice Graphics Memory Test.

Authors:  Zilong Liu; Juan Dong; Xiaohong Zhao; Xiaorui Chen; Sara M Lippa; Jerome S Caroselli; Xiang Fang
Journal:  Brain Behav       Date:  2016-10-13       Impact factor: 2.708

8.  A unifying theory for cognitive abnormalities in functional neurological disorders, fibromyalgia and chronic fatigue syndrome: systematic review.

Authors:  Tiago Teodoro; Mark J Edwards; Jeremy D Isaacs
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-05-07       Impact factor: 10.154

9.  The relationship between initial physical examination findings and failure on objective validity testing during neuropsychological evaluation after pediatric mild traumatic brain injury.

Authors:  Aaron J Provance; E Bailey Terhune; Christine Cooley; Patrick M Carry; Amy K Connery; Glenn H Engelman; Michael W Kirkwood
Journal:  Sports Health       Date:  2014-09       Impact factor: 3.843

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.